Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study ; volume:13 ; number:1 ; day:24 ; month:7 ; year:2023 ; pages:1-9 ; date:12.2023
Scientific reports ; 13, Heft 1 (24.7.2023), 1-9, 12.2023
- Creator
-
Tashiro, Ryota
Kawazoe, Hitoshi
Mamishin, Kanako
Seto, Keisuke
Udagawa, Ryoko
Saito, Yoshimasa
Hashimoto, Hironobu
Shimoi, Tatsunori
Yonemori, Kan
Yonemura, Masahito
Terakado, Hiroyuki
Nishimura, Takahiro
Kawasaki, Toshikatsu
Furukawa, Tetsuya
Nakamura, Tomonori
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-39224-0
- URN
-
urn:nbn:de:101:1-2023102616413254603221
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tashiro, Ryota
- Kawazoe, Hitoshi
- Mamishin, Kanako
- Seto, Keisuke
- Udagawa, Ryoko
- Saito, Yoshimasa
- Hashimoto, Hironobu
- Shimoi, Tatsunori
- Yonemori, Kan
- Yonemura, Masahito
- Terakado, Hiroyuki
- Nishimura, Takahiro
- Kawasaki, Toshikatsu
- Furukawa, Tetsuya
- Nakamura, Tomonori
- SpringerLink (Online service)
Other Objects (12)
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
Long lasting response with trabectedin monotherapy in relapsed metastatic mesenchymal chondrosarcoma
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
Long lasting response with trabectedin monotherapy in relapsed metastatic mesenchymal chondrosarcoma
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
Long lasting response with trabectedin monotherapy in relapsed metastatic mesenchymal chondrosarcoma
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report